File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Role of portal vein embolisation in hepatocellular carcinoma management and its effect on recurrence: an intention-to-treat analysis

TitleRole of portal vein embolisation in hepatocellular carcinoma management and its effect on recurrence: an intention-to-treat analysis
Authors
KeywordsMedical sciences
Endocrinology
Issue Date2011
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 475, abstract PP36-14 How to Cite?
AbstractBACKGROUND: Portal vein embolisation (PVE) for hepatocellular carcinoma is complicated due to the presence of background liver disease, issue of progression of the primary tumor, and possible effect on micrometastasis on the contralateral side. Patients and methods: Fifty-four patients with inadequate functional residual liver volume (FRLV) were offered PVE during a seven-year period. Clinicopathological features were compared between 34 (63%) patients who had undergone curative resection and others. A control group was selected by matching each patient who underwent surgery after PVE (PVE group) with three controls having surgery without PVE. Cases were matched for vascular invasion, type of resection and year of surgery. Postoperative complication pattern of recurrence and survival were compared. RESULTS: PVE increased the FRLV in 66% of the cirrhotic patients. Combination of PVE and surgery was effective in 60% (n = 32) of patients. Minor (control, 29%; PVE, 24%; p = 0.12) and major (PVE, 18%; control, 15%; p = 0.78) complications were similar between PVE and control groups. After a follow-up of 35 months (standard deviation 25 months), extrahepatic recurrence was detected in 10 (31%) and 41 (40%) cases in the PVE group and the control group, respectively (p = 0.25) and intrahepatic recurrence in 10 (29%) and 47 (46%) cases, respectively (p = 0.09). In the PVE group, 41% (n = 14) of the recurrences were detected before one year, compared to 42% (n = 43) in the control group (p = 1). Disease-free survival at 1, 3 and 5 years was 57, 29 and 26%, respectively, in the control group and 60, 42 and 42%, respectively, in the PVE group (log-rank, p = 0.33). On multivariate analysis, PVE was not an individual factor affecting survival (p = 0.82). CONCLUSION: PVE increases resectability and gives patients with hepatocellular carcinoma comparable outcomes.
Descriptionpp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011
Persistent Identifierhttp://hdl.handle.net/10722/136099
ISSN
2015 Impact Factor: 1.125
2015 SCImago Journal Rankings: 0.669
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSiriwardana, RCen_US
dc.contributor.authorLo, CMen_US
dc.contributor.authorChan, SCen_US
dc.contributor.authorChok, KSHen_US
dc.contributor.authorTsang, SHYen_US
dc.contributor.authorCheung, TTen_US
dc.contributor.authorSharr, WWen_US
dc.contributor.authorChan, Aen_US
dc.contributor.authorFan, STen_US
dc.date.accessioned2011-07-27T02:02:48Z-
dc.date.available2011-07-27T02:02:48Z-
dc.date.issued2011en_US
dc.identifier.citationThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 475, abstract PP36-14en_US
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/136099-
dc.descriptionpp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011-
dc.description.abstractBACKGROUND: Portal vein embolisation (PVE) for hepatocellular carcinoma is complicated due to the presence of background liver disease, issue of progression of the primary tumor, and possible effect on micrometastasis on the contralateral side. Patients and methods: Fifty-four patients with inadequate functional residual liver volume (FRLV) were offered PVE during a seven-year period. Clinicopathological features were compared between 34 (63%) patients who had undergone curative resection and others. A control group was selected by matching each patient who underwent surgery after PVE (PVE group) with three controls having surgery without PVE. Cases were matched for vascular invasion, type of resection and year of surgery. Postoperative complication pattern of recurrence and survival were compared. RESULTS: PVE increased the FRLV in 66% of the cirrhotic patients. Combination of PVE and surgery was effective in 60% (n = 32) of patients. Minor (control, 29%; PVE, 24%; p = 0.12) and major (PVE, 18%; control, 15%; p = 0.78) complications were similar between PVE and control groups. After a follow-up of 35 months (standard deviation 25 months), extrahepatic recurrence was detected in 10 (31%) and 41 (40%) cases in the PVE group and the control group, respectively (p = 0.25) and intrahepatic recurrence in 10 (29%) and 47 (46%) cases, respectively (p = 0.09). In the PVE group, 41% (n = 14) of the recurrences were detected before one year, compared to 42% (n = 43) in the control group (p = 1). Disease-free survival at 1, 3 and 5 years was 57, 29 and 26%, respectively, in the control group and 60, 42 and 42%, respectively, in the PVE group (log-rank, p = 0.33). On multivariate analysis, PVE was not an individual factor affecting survival (p = 0.82). CONCLUSION: PVE increases resectability and gives patients with hepatocellular carcinoma comparable outcomes.-
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0-
dc.relation.ispartofHepatology Internationalen_US
dc.rightsThe original publication is available at www.springerlink.com-
dc.subjectMedical sciences-
dc.subjectEndocrinology-
dc.titleRole of portal vein embolisation in hepatocellular carcinoma management and its effect on recurrence: an intention-to-treat analysisen_US
dc.typeConference_Paperen_US
dc.identifier.emailSiriwardana, RC: rohan@hku.hken_US
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_US
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hken_US
dc.identifier.emailCheung, TT: cheung68@hku.hken_US
dc.identifier.emailChan, A: acchan@hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.authorityLo, CM=rp00412en_US
dc.identifier.authorityChan, SC=rp01568en_US
dc.identifier.authorityChan, A=rp00310en_US
dc.identifier.doi10.1007/s12072-010-9241-z-
dc.identifier.hkuros188354en_US
dc.identifier.volume5en_US
dc.identifier.issue1-
dc.identifier.spage475en_US
dc.identifier.epage475en_US
dc.identifier.isiWOS:000300105300001-
dc.publisher.placeUnited States-
dc.description.otherThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 475, abstract PP36-14-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats